Dr Ryan Haumschild Explains How Technology Can Help Practices Juggle Multiple Biosimilars
November 20th 2022Technology utilizing electronic medical records pathways can be useful for practices struggling to manage multiple biosimilars for the same reference product, according to Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute.
In Sight: The Future of Biosimilars in Ophthalmology Care
November 14th 2022A moderated digital open forum facilitated an interactive discussion among health care professionals, health system executives, health care payers, and health policy influencers about promise and the barriers to the expanded use of biosimilars in ophthalmic applications.
Dr Ryan Haumschild: What Health Systems Can Learn From Emory Healthcare's Biosimilar Strategy
October 30th 2022Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, offers advice to health systems on how they can incorporate some of Emory Healthcare's strategies to promote biosimilar uptake.
Dr Nabil Saba Shares His Hope for Future Opdivo, Keytruda Biosimilars
October 12th 2022Nabil Saba, MD, a medical oncologist and immunotherapy specialist in the treatment of head and neck cancer at Emory Healthcare and the Winship Cancer Institute, explained how the eventual introduction of biosimilars for Opdivo (nivolumab) and Keytruda (pembrolizuamb) will help patients with head and neck cancer.
Dr Ryan Haumschild Compares Viewpoints on Biosimilar Value Between Stakeholders
October 4th 2022Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, explains how stakeholders may view the economic value of biosimilars differently based on their goals and his predictions for how biosimilar utilization will develop in the future.
Coherus Rep Discusses Interchangeable Ophthalmology Biosimilar, Previews Onpro Competitor
September 28th 2022Part 5 available now! Paul Reider, MBA, chief commercial officer at Coherus Biosciences, chronicles why Coherus got an interchangeable designation for its ophthalmology biosimilar, how it plans to set its adalimumab biosimilar apart from the rest, and when the pegfilgrastim market could see a competitor for Neulasta Onpro.
Julie Reed On How the Biosimilars Forum is Helping FDA Catch Up on Biosimilar Inspections
July 17th 2022Julie M. Reed, the executive director of the Biosimilars Forum, dives into the efforts that the Forum is taking to ensure that FDA can catch up on their inspections backlog and get biosimilar approvals back on track.
Gillian Woollett Speaks on Where Biosimilar Conversations Need to Go Moving Forward
June 26th 2022Although a lot of discussion regarding biosimilars has focussed on patient access, we need to divert more attention to the reliability of companies making biosimilar products, said Gillian Woollett, MA, DPhil, vice president and head of regulatory strategy and policy at Samsung Bioepis.
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
June 22nd 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing number of biosimilars referencing Humira (adalimumab) that are expected to enter the market in 2023 and beyond.
Julie Reed: Biosimilar Policies Legislators Should Be Prioritizing
June 19th 2022The Biden administration must follow through on its promises, and Congressional leaders must do more to push through bipartisan biosimilar policies to encourage better adoption and lower drug costs, according to Julie M. Reed, the executive director of the Biosimilars Forum.
Gillian Woollett Catalogues How Conversations Surrounding Biosimilars Evolved
June 12th 2022Gillian Woollett, MA, DPhil, vice president and head of regulatory strategy and policy at Samsung Bioepis, outlines how concerns over the safety and efficacy of biosimilars has shifted and what new concerns the industry is focusing on.